Disclosure of pharmacokinetic drug results to understand nonadherence.

摘要: OBJECTIVES In VOICE, a phase IIB trial of daily oral and vaginal tenofovir for HIV prevention, at least 50% women receiving active products had undetectable in all plasma samples tested. MTN-003D, an ancillary study using in-depth interviews (IDIs) focus group discussions (FGDs), together with retrospective disclosure pharmacokinetic results, explored adherence challenges during VOICE. METHODS We systematically recruited participants data (median six samples), categorized as low (0%, N = 79), inconsistent (1-74%, N = 28) or high (≥75%; N = 20) on the basis frequency detection. Following reactions were captured elicited; IDIs FGDs audio-recorded, transcribed, coded thematically analysed. RESULTS interviewed 127 from South Africa, Uganda Zimbabwe. The most common to results included surprise (41%; pharmacokinetic), acceptance (39%; pharmacokinetic) happiness (65%; pharmacokinetic). On participants' explanations, we developed typology patterns: noninitiation, discontinuation, misimplementation (resulting visit-driven use, variable taking, modified dosing regimen) adherence. Fear product side effects/harm was frequent concern, fuelled by stories shared among participants. Although levels reported similar concerns, several described strategies overcome challenges. Women suggested real-time drug monitoring feedback improve reporting. CONCLUSION Retrospective provision seemingly promoted candid around nonadherence participation. effect accuracy reporting should be evaluated trials.